# DEA Selects Only Cannabis Opponents For Crucial June 29 Rescheduling Hearing > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/dea-selects-only-cannabis-opponents-for-crucial-june-29-rescheduling-hearing/ > **Published:** 2026-06-19T12:15:42-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T16:59:27-04:00 > **Clinical Summary:** DEA rescheduling hearing and emerging opioid reduction data shape cannabis prescribing access. Clinical guidance on regulatory impact and evidence evaluation. --- ✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyResearchSafetyMental HealthPainAnxietyIndustry Why This Matters # ResponseClinicians need to understand that the DEA’s hearing panel composition may influence rescheduling decisions that directly affect their ability to prescribe cannabis and access clinical evidence for [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/). If cannabis scheduling changes, clinicians will need updated guidance on dosing, drug interactions, and appropriate clinical applications, particularly for [pain management](https://cedclinic.com/cbd-cbg-topicals-for-eczema/) where opioid alternatives are increasingly sought. The withheld French study on opioid reduction represents critical evidence that regulators and clinicians should have access to when making evidence-based treatment decisions for their patients. Clinical Summary The DEA’s selection of only cannabis opponents as witnesses for a critical June 29 rescheduling hearing raises concerns about the fairness and scientific rigor of the scheduling review process, potentially limiting evidence-based perspectives on cannabis rescheduling. Meanwhile, France’s July deadline for [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) regulations, coupled with emerging data suggesting cannabis may reduce opioid consumption, highlights diverging international approaches to cannabis policy and the growing clinical evidence supporting therapeutic applications. The lack of balanced representation at the DEA hearing may delay or impede the consideration of pharmacological evidence that could inform more nuanced scheduling decisions aligned with clinical outcomes. For clinicians, this regulatory disparity underscores the importance of staying informed about evolving international cannabis policies while recognizing that current U.S. scheduling restrictions may not fully reflect emerging clinical data on safety and efficacy in opioid-reduction strategies. Physicians should advocate for evidence-based participation in regulatory proceedings and remain aware that policy decisions affecting patient access may be influenced by processes that do not equally represent scientific evidence and clinical perspectives. Clinical Perspective 💊 The composition of advisory panels evaluating cannabis rescheduling carries significant implications for clinical practice, as selective representation may skew the evidence base informing policy decisions that affect prescribing guidelines and patient access. Healthcare providers should remain aware that regulatory processes, while important, may not always reflect the full spectrum of published evidence regarding cannabis efficacy for specific conditions, particularly emerging data on opioid reduction potential shown in international studies. The tension between regulatory caution and clinical evidence is understandable given cannabis’s complex pharmacology and variable product quality, but providers should independently review peer-reviewed literature rather than relying solely on regulatory assessments to inform individualized patient discussions. As jurisdictions like France move toward clearer [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) frameworks, clinicians in regions with evolving policy landscapes should develop familiarity with the current evidence on cannabinoid safety and efficacy for their patient populations. For now, documenting patient-specific rationales for cannabis discussions and maintaining awareness of 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20DEA%20Selects%20Only%20Cannabis%20Opponents%20For%20Crucial%20June%2029%20Rescheduling%20Hearing%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59669)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59669)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20DEA%20Selects%20Only%20Cannabis%20Opponents%20For%20Crucial%20June%2029%20Rescheduling%20Hearing%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59669)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://businessofcannabis.com/dea-selects-only-cannabis-opponents-for-crucial-june-29-rescheduling-hearing/](https://businessofcannabis.com/dea-selects-only-cannabis-opponents-for-crucial-june-29-rescheduling-hearing/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).